Ianalumab

Latest news

Tag

Adding Ianalumab to Ibrutinib Induces Deep Remissions and Enables Therapy Discontinuation in Chronic Lymphocytic Leukemia

A Phase Ib study reveals that adding the anti-BAFF-R antibody ianalumab to ibrutinib therapy achieves high rates of undetectable measurable residual disease (uMRD), allowing over 40% of CLL patients to successfully discontinue long-term tre

Jan 13, 2026

Hematology-Oncology

Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia

The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thro

Dec 18, 2025

Hematology-Oncology

B-Cell Depletion Meets TPO-RA: Ianalumab and Eltrombopag Redefine Treatment Success in Immune Thrombocytopenia

The Phase 3 VAYHIT2 trial reveals that combining ianalumab with eltrombopag significantly extends freedom from treatment failure and increases stable response rates in patients with second-line immune thrombocytopenia, potentially offering

Dec 18, 2025